drugset / Trial / NCT03864575
An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label study to evaluate the safety and the anti-tumor activity of the combination of nivolumab and celecoxib. The total numbers of participants to be enrolled will be up to 68 participants, depending on the investigated dose of celecoxib during the safety run-in phase.
Timeline
- Start
- 2019-08-15
- Primary completion
- 2021-06-15
- Completion
- 2021-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 400 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |